GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Biocon Ltd

Biocon Ltd Allots Shares on Preferential Basis to Fund BBL Acquisition

FUNDRAISE ▲ Positive Development LOW RISK
📅 Filed on BSE: 29 Jun 2026, 10:33 PM IST  ·  BSE ID: 1687e2f1-1576-47ca-b4f7-a33866b3bfc6
View Original BSE Filing (PDF)
💡
In Simple Terms
Biocon just bought more shares in its subsidiary Biocon Biologics by giving its own shares to the sellers. This makes the subsidiary fully owned.
🤖 AI Summary
  • Biocon Limited completed acquisition of 1,15,36,956 equity shares of Biocon Biologics Limited.
  • Issued and allotted 87,86,362 equity shares of Biocon on preferential basis.
  • Allotment serves as consideration for Biocon Biologics acquisition from 127 shareholders.
  • Biocon Biologics is now a wholly-owned subsidiary of Biocon Limited effective June 29, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
BBL equity shares acquired
1,15,36,956
Biocon equity shares allotted
87,86,362
Allotment issue price per share
Rs. 376.41
Original equity share capital
Rs. 8,10,45,38,865/-
New equity share capital
Rs. 8,14,84,70,675/-
Original number of equity shares
1,62,09,07,773
New number of equity shares
1,62,96,94,135
🏢 How This Affects the Company
📈
Business Impact
Biocon Limited now wholly owns Biocon Biologics, consolidating control over its biologics business operations and strategic direction. This integration simplifies reporting and potential future funding structures.
💰
Financial Impact
The issuance of 87,86,362 equity shares has increased Biocon Limited's issued, subscribed, and paid-up equity share capital. The total equity share capital now stands at Rs. 8,14,84,70,675/-.
⚙️
Operational Impact
No direct operational changes are detailed in this filing, but full ownership of Biocon Biologics streamlines organizational structure and decision-making processes.
⚠️
Risk Impact
Consolidating a subsidiary under full ownership can reduce complexity and potential conflicts of interest among minority shareholders, thereby marginally decreasing certain operational risks.
👥 What This Means For Shareholders
✅
Action Required
No action is required from existing shareholders. The issuance of new shares will dilute existing holdings proportionally.
👤
Who Is Affected
Existing equity shareholders are affected by a proportional dilution of their shareholding percentage due to the issuance of new shares.
🔍
Management Signal
Management signals a commitment to consolidating strategic assets like Biocon Biologics under full group control for unified strategy execution.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Confirmation of Biocon Biologics' financial consolidation in future results.
Any strategic announcements regarding the integration of Biocon Biologics.
Updates on Biocon Limited's consolidated debt and cash position.
LOW RISK Routine preferential allotment and consolidation of a subsidiary.
💡 Investor Takeaway
Biocon Limited completed the acquisition of 1,15,36,956 Biocon Biologics shares by issuing 87,86,362 Biocon shares, making Biocon Biologics a wholly-owned subsidiary.
⚖️ Strengths & Concerns

✅ Positives

  • Completed acquisition of subsidiary shares, increasing ownership to 100%.
  • Issued 87,86,362 equity shares at Rs. 376.41 per share, a specific transaction value.
❓ Frequently Asked Questions
What did Biocon Limited acquire on June 29, 2026?
Biocon Limited completed the acquisition of 1,15,36,956 equity shares of Biocon Biologics Limited.
How many equity shares did Biocon Limited allot on preferential basis?
Biocon Limited allotted 87,86,362 equity shares on a preferential basis.
What was the issue price for the preferential allotment?
The issue price for the preferential allotment was Rs. 376.41 per equity share.
What is the new total equity share capital of Biocon Limited?
The issued, subscribed, and paid-up equity share capital of Biocon Limited increased to Rs. 8,14,84,70,675/-.
What is the status of Biocon Biologics Limited after this transaction?
Biocon Biologics Limited has become a wholly-owned subsidiary of Biocon Limited.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.